| Literature DB >> 34130648 |
Tatsuo Matsuda1, Yuzo Umeda2, Tadakazu Matsuda1, Yoshikatsu Endo3, Daisuke Sato4, Toru Kojima5, Kenta Sui6, Masaru Inagaki7, Tetsuya Ota8, Masayoshi Hioki9, Masahiro Oishi10, Masashi Kimura11, Toshihiro Murata12, Nobuhiro Ishido13, Takahito Yagi14, Toshiyoshi Fujiwara14.
Abstract
BACKGROUND: In the surgical treatment of intrahepatic cholangiocarcinoma (ICC), postoperative complications may be predictive of long-term survival. This study aimed to identify an immune-nutritional index (INI) that can be used for preoperative prediction of complications. PATIENTS AND METHODS: Multi-institutional data from 316 patients with ICC who had undergone surgical resection were retrospectively analysed, with a focus on various preoperative INIs.Entities:
Keywords: Intrahepatic cholangiocarcinoma; Postoperative complication; Prognostic nutritional index
Year: 2021 PMID: 34130648 PMCID: PMC8207701 DOI: 10.1186/s12885-021-08424-0
Source DB: PubMed Journal: BMC Cancer ISSN: 1471-2407 Impact factor: 4.430
Summary of all postoperative complications
| Complications | Total number (%) | Grade of surgical complication | |||
|---|---|---|---|---|---|
| None | I-II | III-IV | V | ||
| No complications - Grade II (%) | 250 (79.1%) | 205 (64.8%) | 45 (14.2%) | ||
| Grade III-V (%) | 66 (20.8%) | 59 (18.6%) | 7 (2.2%) | ||
| Total no. of complications (%) | 111 (35.2%) | ||||
| heart failure | 2 (0.6%) | 1 (0.3%) | 1 (0.3%) | ||
| deep venous thrombosis | 2 (0.6%) | 2 (0.6%) | |||
| pleural effusion | 4 (1.3%) | 2 (0.6%) | 2 (0.6%) | ||
| pneumonia | 1 (0.3%) | 1 (0.3%) | |||
| gastrointestinal hemorrhage | 4 (1.3%) | 2 (0.6%) | 1 (0.3%) | 1 (0.3%) | |
| delayed gastric empting | 15 (4.7%) | 14 (4.4%) | 1 (0.3%) | ||
| intestinal obstruction | 5 (1.6%) | 2 (0.6%) | 3 (0.9%) | ||
| superficial-deep wound | 8 (2.5%) | 7 (2.2%) | 1 (0.3%) | ||
| intra-abdominal abscess | 16 (5.1%) | 1 (0.3%) | 14 (4.4%) | 1 (0.3%) | |
| bile leak | 37 (11.7%) | 6 (1.9%) | 31 (9.8%) | ||
| portal vein thrombosis | 4 (1.3%) | 4 (1.3%) | |||
| anastomotic leak | 1 (0.3%) | 1 (0.3%) | |||
| intra-abdominal hemorrhage | 3 (0.9%) | 1 (0.3%) | 1 (0.3%) | 1 (0.3%) | |
| sepsis | 3 (0.9%) | 2 (0.6%) | 1 (0.3%) | ||
| ascites | 6 (1.9%) | 4 (1.3%) | 2 (0.6%) | ||
aClavien-Dindo classification
Fig. 1Receiver operating characteristic curves for immune-nutritional indices related to severe postoperative complications
Comparisons of each AUC for predicting postoperative complications
| Variables | difference | Standard error | 95%CI | ×2 | ||
|---|---|---|---|---|---|---|
| PNI vs NLR | 0.131 | 0.043 | 0.045 | 0.215 | 9.061 | 0.003 |
| PNI vs LMR | 0.073 | 0.039 | −0.004 | 0.149 | 3.415 | 0.064 |
| PNI vs CONUTS | 0.095 | 0.028 | 0.040 | 0.151 | 11.394 | < 0.001 |
| LMR vs NLR | 0.058 | 0.042 | −0.025 | 0.141 | 1.888 | 0.169 |
| LMR vs CONUTS | 0.023 | 0.044 | −0.064 | 0.109 | 0.278 | 0.600 |
| NLR vs CONUTS | −0.035 | 0.045 | −0.123 | 0.052 | 0.617 | 0.431 |
Clinicopathological characteristics of the low PNI group and the high PNI group
| Variables | All patients ( | Low PNI group | High PNI group | P-value* |
|---|---|---|---|---|
| PNI < 50 ( | PNI ≥ 50 ( | |||
| Male, n (%) | 187 (59.1%) | 100 (57.5%) | 87 (61.3%) | 0.495 |
| Age (years), median (IQR) | 71 (63–76) | 72.5 (66–79) | 68 (62–74) | 0.002 |
| BMI, median (IQR) | 22.1 (20.0–24.8) | 22.0 (19.2–24.0) | 22.8 (21.0–25.2) | 0.048 |
| Lymphocytes (/ul), median (IQR) | 1560 (1190-1931) | 1328 (1058-1625) | 1894 (1508-2332) | <.0001 |
| Neutrophils (/ul), median (IQR) | 3652 (2834-4908) | 3692 (2781-5027) | 3634 (2920-4474) | 0.759 |
| Monocytes (/ul), median (IQR) | 342 (277–440) | 342 (270–436) | 342 (281–442) | 0.669 |
| Platelet count (104/uL), median (IQR) | 19.9 (15.4–24.5) | 19.9 (14.5–25.4) | 20.1 (16.8–23.6) | 0.827 |
| Total Bilirubin (mg/dl), median (IQR) | 0.7 (0.5–0.9) | 0.7 (0.50–0.90) | 0.7 (0.54–0.90) | 0.698 |
| Albumin (mg/dl), median (IQR) | 4.1 (3.8–4.4) | 3.8 (3.5–4.1) | 4.3 (4.3–4.6) | <0.001 |
| AST (U/L), median (IQR) | 29 (22–39) | 29 (22–42) | 29 (23–37) | 0.978 |
| ALT (U/L), median (IQR) | 25 (16–39) | 24 (15–39) | 27 (18–38) | 0.142 |
| Prothrombin time (INR), median (IQR) | 1.03 (0.97–1.10) | 1.04 (1.0–1.13) | 1.01 (0.95–1.07) | <.0001 |
| Total Cholesterol (mg/dL), median (IQR) | 185 (166–211) | 180 (156–206) | 194 (173–220) | 0.015 |
| HBV-Ag, n (%) | 18 (5.7%) | 11 (6.3%) | 7 (4.9%) | 0.595 |
| HCV-Ab, n (%) | 47 (14.9%) | 29 (16.7%) | 18 (12.7%) | 0.321 |
| CRP (mg/dl), median (IQR) | 0.2 (0.09–0.70) | 0.3 (0.10–1.04) | 0.16 (0.08–0.34) | 0.010 |
| Preoperative chemotherapy, n (%) | 7 (2.2%) | 6 (3.5%) | 1 (0.7%) | 0.099 |
| Morphology, n (%) | ||||
| Mass-forming (MF) | 234 (74.5%) | 123 (71.1%) | 111 (78.7%) | 0.260 |
| Periductal-infiltrating (PI) | 30 (9.6%) | 16 (9.3%) | 14 (9.9%) | |
| MF+PI | 34 (10.8%) | 23 (13.3%) | 11 (7.8%) | |
| Intraductal Growth | 16 (5.1%) | 11 (6.3%) | 5 (3.6%) | |
| Tumor size (cm), median (IQR) | 4.0 (2.8–6.5) | 4.5 (3.0–7.0) | 4.0 (2.5–6.0) | 0.253 |
| Multi-nodular, n (%) | 63 (19.9%) | 35 (20.1%) | 28 (19.7%) | 0.930 |
| Localization, n (%) | ||||
| Hilar | 111 (35.1%) | 72 (41.4%) | 39 (27.5%) | 0.010 |
| Peripheral | 205 (64.9%) | 102 (58.6%) | 103 (72.5%) | |
| CEA (ng/ml), median (IQR) | 2.90 (1.80–5.87) | 3.1 (2.0–7.2) | 2.8 (1.6–4.7) | 0.323 |
| CA19–9 (U/ml), median (IQR) | 39.4 (14.3–246.9) | 52.1 (15.8–356.2) | 26.3 (14.1–127.9) | 0.024 |
| Major hepatectomy, n (%) | 222 (70.3%) | 128 (73.5%) | 94 (66.2%) | 0.154 |
| Type of hepatectomy, n (%) | ||||
| Segmentectomy/Sub-segmentectomy | 82 (25.9%) | 39 (22.4%) | 43 (30.3%) | 0.196 |
| Hemihepatectomy | 221 (69.9%) | 126 (72.4%) | 95 (66.9%) | |
| Trisectionectomy | 13 (4.1%) | 9 (5.2%) | 4 (2.82%) | |
| Lymphnode dissection, n (%) | 218 (68.9%) | 117 (67.2%) | 101 (71.1%) | 0.458 |
| Bile duct resection, n (%) | 82 (25.9%) | 53 (30.4%) | 29 (20.4%) | 0.043 |
| Vascular reconstruction**, n (%) | 24 (7.5%) | 16 (9.2%) | 8 (5.6%) | 0.235 |
| Blood loss (ml), median (IQR) | 670 (350–1208) | 780 (380–1190) | 640 (304–1250) | 0.499 |
| Operation time (min), median (IQR) | 348 (270–448) | 354 (271–465) | 333 (264–420) | 0.228 |
| Serosa invasion, n (%) | 112 (35.4%) | 58 (33.3%) | 54 (38.0%) | 0.386 |
| Vascular invasion, n(%) | 160 (50.6%) | 87 (50.0%) | 73 (51.4%) | 0.947 |
| Lymph node metastasis, n(%) | 86 (27.2%) | 47 (27.0%) | 39 (27.5%) | 0.528 |
| Differentiation, n (%) | 0.221 | |||
| Well | 66 (20.9%) | 37 (21.3%) | 29 (20.4%) | |
| Moderate | 167 (52.9%) | 84 (48.3%) | 83 (58.4%) | |
| Poorly | 58 (18.4%) | 36 (20.7%) | 22 (15.5%) | |
| Un-classified | 25 (7.9%) | 17 (8.7%) | 8 (5.6%) | |
| Background liver, n (%) | 0.302 | |||
| Normal | 234 (74.0%) | 123 (70.7%) | 111 (78.2%) | |
| Hepatitis | 60 (19.0%) | 38 (21.8%) | 22 (15.5%) | |
| Fibrosis | 22 (7.0%) | 13 (7.5%) | 9 (6.3%) | |
| Clavien-Dindo classification, n (%) | 0.019 | |||
| none | 205 (64.9%) | 103 (59.2%) | 102 (71.8%) | |
| Grade I-II | 45 (14.2%) | 24 (13.8%) | 21 (14.8%) | |
| Grade III-IV | 58 (18.4%) | 40 (23.0%) | 18 (12.7%) | |
| Grade V | 8 (2.5%) | 7 (4.0%) | 1 (0.7%) | |
| All Complication. CD-Grade I-V | 111 (35.1%) | 71 (40.8%) | 40 (28.2%) | 0.019 |
| All Complication. CD-Grade III-V | 66 (20.9%) | 47 (27.0%) | 19 (13.4%) | 0.003 |
| Infectious Complication. CD-Grade I-V | 31 (9.8%) | 26 (14.9%) | 5 (3.5%) | 0.002 |
| Infectious Complication. CD-Grade IIII-V | 19 (6.0%) | 17 (36.2%) *** | 2 (10.5%) *** | 0.037 |
| Adjuvant chemotherapy, n (%) | 122 (38.6%) | 57 (32.7%) | 65 (45.7%) | 0.018 |
* Low-PNI group vs High-PNI group
** reconstruction of portal vein or hepatic artery or hepatic vein or inferior vene cava
*** proportion in complicated cases
Fig. 2a. Frequency of postoperative infectious complications in all patients (n=316). b. Frequency of postoperative infectious complications in patients with severe complications (n=66)
Logistic regression analysis to examine risk factors for major postoperative complications
| Variables | Univariate analysis | Multivariate analysis | ||||||
|---|---|---|---|---|---|---|---|---|
| Odds ratio | 95% C.I. | Odds ratio | 95% C.I. | |||||
| Age: ≥80 vs < 80 (years) | 1.965 | 1.009 | 3.828 | 0.046 | 1.575 | 0.752 | 3.298 | 0.228 |
| BMI | 0.959 | 0.886 | 1.037 | 0.291 | ||||
| Platelet count (104/uL) | 1.016 | 0.981 | 1.051 | 0.370 | ||||
| Total Bilirubin (mg/dl) | 1.062 | 0.863 | 1.309 | 0.566 | ||||
| PNI: < 50 vs ≥ 50 | 2.395 | 1.331 | 4.312 | 0.002 | 2.072 | 1.143 | 3.961 | 0.027 |
| AST (U/L) | 1.001 | 0.998 | 1.005 | 0.308 | ||||
| ALT (U/L) | 1.003 | 0.998 | 1.009 | 0.183 | ||||
| Prothrombin time (INR) | 1.106 | 0.184 | 6.623 | 0.912 | ||||
| Total Cholesterol (mg/dL) | 1.001 | 0.995 | 1.006 | 0.717 | ||||
| CRP (mg/dl) | 1.082 | 0.970 | 1.207 | 0.162 | ||||
| Preoperative chemotherapy | 2.928 | 0.639 | 13.42 | 0.167 | ||||
| Morphology: Mass-forming vs the other type | 0.806 | 0.440 | 1.479 | 0.487 | ||||
| Tumor size (cm) | 1.049 | 0.957 | 1.151 | 0.298 | ||||
| Multi-nodular | 1.382 | 0.724 | 2.637 | 0.326 | ||||
| Localization: Hilar vs Peripheral | 2.523 | 1.151 | 5.530 | 0.020 | 2.548 | 1.143 | 5.683 | 0.022 |
| CEA (ng/ml) | 1.003 | 0.992 | 1.013 | 0.608 | ||||
| CA19–9 (U/ml) | 1.000 | 0.999 | 1.000 | 0.827 | ||||
| Vascular invasion* | 1.172 | 0.680 | 2.020 | 0.566 | ||||
| Lymph node metastasis | 1.122 | 0.579 | 2.171 | 0.732 | ||||
| Tumor differentiation: mod/por vs well | 1.662 | 0.889 | 3.111 | 0.112 | ||||
| Major hepatectomy vs Minor hepatectomy | 1.570 | 0.832 | 2.962 | 0.153 | ||||
| Lymph node dissection | 1.254 | 0.686 | 2.294 | 0.460 | ||||
| Bile duct resection | 3.456 | 1.948 | 6.129 | 0.001 | 1.135 | 0.491 | 2.625 | 0.767 |
| Vascular reconstruction** | 2.473 | 1.030 | 5.937 | 0.042 | 1.061 | 0.393 | 2.870 | 0.906 |
| Blood loss (ml) | 1.001 | 1.000 | 1.001 | 0.032 | 1.000 | 0.999 | 1.000 | 0.612 |
| Operation time (min) | 1.004 | 1.002 | 1.006 | 0.001 | 1.003 | 1.000 | 1.006 | 0.026 |
*vascular invasion: pathologically diagnosed as invasion to portal vein, hepatic artery, hepatic vein, and inferior vena cava
**reconstruction including portal vein, hepatic artery, hepatic vein, and inferior vena cava
Fig. 3a. Kaplan-Meier curves for postoperative overall survival, stratified by grade of postoperative complications. b. Kaplan-Meier curves for postoperative overall survival, stratified by PNI. c. Kaplan-Meier curves for postoperative overall survival, stratified by grade of postoperative complications in the low-PNI group. d. Kaplan-Meier curves for postoperative overall survival, stratified by grade of postoperative complications in the high-PNI group
Fig. 4a. Kaplan-Meier curves for postoperative overall survival in patients without adjuvant chemotherapy (n=194). b. Kaplan-Meier curves for postoperative overall survival in patients with adjuvant chemotherapy (n=122)